Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from Kintor Pharmaceutical Ltd ( (HK:9939) ).
Kintor Pharmaceutical Ltd reported a significant improvement in its financial performance for the year ended December 31, 2024. The company’s revenue increased to RMB5.0 million, driven by global sales of its new cosmetics brand, KOSHINÉ. The net loss decreased by 85.4% due to reduced R&D costs, which fell by 91.7% as the company shifted its focus to more cost-effective dermatology pipelines. Administrative expenses also decreased, while marketing costs rose significantly to promote the cosmetics business. With cash reserves and unutilized bank credit, Kintor is poised to continue supporting its clinical trials and R&D efforts.
More about Kintor Pharmaceutical Ltd
Kintor Pharmaceutical Ltd is a company incorporated in the Cayman Islands, primarily engaged in the pharmaceutical industry. The company focuses on developing innovative treatments, with a particular emphasis on dermatology and oncology pipelines. Recently, it has expanded into the cosmetics market with the launch of its high-end brand, KOSHINÉ.
YTD Price Performance: 67.01%
Average Trading Volume: 2,982,440
Technical Sentiment Signal: Hold
Current Market Cap: HK$713.3M
For a thorough assessment of 9939 stock, go to TipRanks’ Stock Analysis page.